Skip to main content
OpenTrials
Completed

NCT Number: NCT03397641

A Phase 1 Study of HBI-3000

This is a Phase 1 randomised, double-blind, placebo-controlled, serial cohort, dose-escalation study in healthy adult volunteers. It is planned to enroll 5 cohorts (Cohorts A to E) of 8 subjects. Up to 2 additional cohorts (Cohorts F and G) may be enrolled as needed to establish the safety profile of HBI-3000 over a clinically relevant range of doses. Subjects will be randomly assigned to receive a single dose of HBI-3000 or matching placebo in a sequential escalating manner (Regimens A to E and optional Regimens F and G), with a minimum of 7 days and a maximum based on logistics of interim review between dose groups.

As a safety precaution, in each cohort a sentinel dosing group of n = 2 (1 active:1 placebo) will be dosed at least 24 h ahead of the main group. Safety and tolerability will be assessed by the principal investigator or medically-qualified designee before continuing with dosing the remaining subjects. The first 2 subjects will be allocated to active or placebo in a 1:1 ratio. The remaining 6 subjects will be allocated to active or placebo in a 5:1 ratio.

Doses of HBI-3000 may range from 20 mg to a level at which it is expected that the drug exposure will not exceed an AUC(0-t) of 20 μg.h/mL and Cmax of 20 μg/mL (based on the no-observed-adverse-effect levels [NOAEL] in both 14 day repeat dose toxicology species the rat and minipig) and the expected therapeutic dose range. Following administration to each cohort, there will be an interim data review during which the PK and safety data will be reviewed to determine the dose to be administered in the next cohort. Dose escalation for serial cohorts will progress unless safety concerns preclude further dose escalation. If the selected dose does not provide the required data, a previously tested dose may be used in a subsequent cohort. However, if the dose level met the dose escalation stopping criteria, that dose level must not be repeated. A previously untested intermediate dose may also be used in a subsequent cohort.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atrial Fibrillation Arrhythmias, Cardiac Cardiovascular Diseases Heart Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Quotient Clinical

Nottingham, NG11 6JS, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males or non-pregnant, non-lactating healthy females
  • Age 18 to 50 years
  • Body mass index of 18.0 to 30.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator
  • Minimum body weight of 60 kg
  • Must be willing and able to communicate and participate in the whole study
  • Normal hepatic function as evidenced by AST and alanine aminotransferase (ALT) <1.5 × ULN and alkaline phosphatase (ALP) and total bilirubin within the normal range
  • Haemodynamically stable with systolic BP 90 to 150 mm Hg, diastolic BP <95 mmHg and resting HR ≥45 and ≤100 bpm
  • Forced expiratory volume in 1 s (FEV1) >80% predicted value and FEV1/ forced vital capacity (FVC) ratio >0.7
  • Must provide written informed consent
  • Must agree to use an adequate method of contraception

Exclusion criteria

  • Subjects who have received any IMP in a clinical research study within the previous 3 months
  • Subjects who are study site employees, or immediate family members of a study site or sponsor employee
  • Subjects who have previously been enrolled in this study.
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  • Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  • Females of childbearing potential who are pregnant or lactating (all female subjects must have a negative pregnancy test). A woman is considered of childbearing potential unless she is permanently sterile (hysterectomy, bilateral salpingectomy and bilateral oophorectomy) or is postmenopausal (had no menses for 12 months without an alternative medical cause and a serum follicle-stimulating hormone [FSH] concentration ≥40 IU/L)
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening
  • Clinically significant abnormal biochemistry, haematology, coagulation or urinalysis as judged by the investigator, including:
  • Serum K <3.5 mmol/L
  • Serum magnesium concentration of <0.7 mmol/L
  • Serum phosphate <2.5 or >4.5 mg/dL
  • Positive drugs of abuse test result
  • Positive hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus (HIV) results
  • Evidence of renal impairment at screening, as indicated by an estimated creatinine clearance of <80 mL/min using the Cockcroft-Gault equation
  • Evidence of any clinically relevant acute or chronic medical illness, including renal, hepatic, haematological, endocrine, pulmonary (including asthma), oncologic, neurologic or gastrointestinal disease, or psychiatric disorder, as judged by the investigator
  • History or presence of clinically significant cardiovascular disease, including coronary artery disease, myocardial infarction or ischemia, congestive heart failure, valvular disease, congenital heart disease or prior cardiac surgery
  • History or presence of cardiac arrhythmia or conduction abnormalities, including long-QT syndrome, TdeP, Wolff-Parkinson-White syndrome or bradycardia (<45 bpm)
  • QTcF interval >450 or QRS >120 msec
  • Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients
  • Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed unless it is active
  • Donation or loss of greater than 400 mL of blood within the previous 3 months
  • Subjects who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 g per day paracetamol and HRT/hormonal contraception) or herbal remedies in the 14 days before IMP administration (see Section 11.4). Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the PI and sponsor's medical monitor.
  • Failure to satisfy the investigator of fitness to participate for any other reason

Treatment and study plan

HBI-3000

Drug

Small molecule, multi-ion channel blocker

Other names: Sulcardine sulfate

Placebo

Other

Normal Saline

Primary outcomes

  1. Physical Examination (Safety and Tolerability)

    Time frame: Change from screening (3 to 28 d prior to dosing), admission (2 d prior to dosing), 48 h post-start of infusion, and 7 d +/- 1 d post-start of infusion (follow-up visit)

    Typical physical examination, including general appearance; head, neck, and thyroid; ears, nose, and throat; cardiovascular; respiratory; lymph nodes; abdomen; dermatological; musculoskeletal; neurological/CNS; ocular/ophthalmology; and other (as specified) evaluation

  2. Safety Labs (Safety and Tolerability)

    Time frame: Change from screening (3 to 28 d prior to dosing), 1 d prior to dosing, 24 h and 48 h post-start of infusion, and 7 d +/- 1 d post-start of infusion (follow-up visit)

    Hematology (hemoglobin[g/L], HCT[%], RBC[x10^12/L], MCV[fL], MCH[pg], MCHC[g/L], platelet[x10^9/L], WBC[x10^9/L], neutrophils[x10^9/L], lymphocytes[x10^9/L], monocytes[x10^9/L], eosinophils[x10^9/L], basophils[x10^9/L], hematocrit[%]), coagulation (prothrombin time[s], APTT[s]), clinical chemistry (Na[mmol/L], K[mmol/L], Cl[mmol/L], bicarbonate[mmol/L], urea[mmol/L], creatinine[µmol/L], bilirubin[µmol/L], direct conj bilirubin[µmol/L], alkaline phosphatase[IU/L], aspartate aminotransferase[IU/L], alanine aminotransferase[IU/L], creatinine kinase[IU/L], gamma glutamyl transferase[IU/L], total protein[g/L], albumin[g/L], Ca[mmol/L], Mg[mmol/L], P[mmol/L], uric acid[µmol/L], random blood glucose[mmol/L], fasting blood glucose[mmol/L], triglycerides[mmol/L], fasting triglycerides[mmol/L], creatinine clearance[mL/min]), virology (Hepatitis B surface[+/-], Antigen[+/-], Hepatitis C[+/-], Antibody[+/-], HIV Antibody[+/-]); and FSH(IU/L) and beta H.C.G. serum(+/-)

  3. Urinalysis (Safety and Tolerability)

    Time frame: Change from screening (3 to 28 d prior to dosing), admission (2 d prior to dosing), 24 h and 48 h post-start of infusion, and 7 d +/- 1 d post-start of infusion (follow-up visit)

    Bilirubin (-/+; +, ++, +++), urobilinogen (-/+; 2, 4, 8, 12 mg/dL), ketones (-/+; trace, +, ++, +++), glucose (-/+; 50, 100, 250, 500, ≥1000 mg/dL), pH (5.0, 6.0, 6.5, 7.0, 8.0, 9.0), hCG (female subjects; -/+), specific gravity (1.000, 1.005, 1.010, 1.015, 1.020, 1.025, 1.030), protein (-/+; trace, 30, 100, 500 mg/dL), blood (-/+; +ca.5-10, ++ca.50, +++ca.300, ca.5-10, ca.50, ca.300 ery/µL), nitrites (-/+; light pink, dark pink), leukocytes (-/+; ca.25, ca.75, ca.500 leuko/µL) (performed using dipsticks; if positive, tick correct result), microbiology (WBS [HPF], RBCS [HPF], hyaline casts [HPF], granular casts [HPF], cellular casts [HPF]) and urine microscopy (both at the discretion of the investigator based on urinalysis results), and drugs of abuse (amphetamines [+/-], barbiturates [+/-], benzodiazepines [+/-], cocaine [+/-], marijuana/cannabis [+/-], methadone [+/-], methamphetamine/ecstasy [+/-], morphine/opiates [+/-], phencyclidine [+/-], tricyclic antidepressants [+/-])

  4. Pulmonary Function Tests (Safety and Tolerability)

    Time frame: Change from screening (3 to 28 d prior to dosing), pre-dose (within 24 h prior to dosing), and 0.75 h and 4 h post-start of infusion

    The following lung function tests will be performed using a standard calibrated spirometer: FEV1 (L), FVC (L), peak expiratory flow rate (PEFR) (L/min), and FEV1/FVC (%)

  5. 12-Lead ECG (Safety and Tolerability)

    Time frame: Change from screening (3 to 28 d prior to dosing), admission (2 d prior to dosing), pre-dose (within 24 h prior to dosing), 0.25 h, immediately prior to end of infusion, 1, 4, 6, 12, 24, and 48 h, and 7 d +/- 1 d post-start of infusion

    Measured after subject has been in supine position for at least 5 min.

  6. Holter ECG (Safety and Tolerability)

    Time frame: Data extractions on Day -1 will be time matched to the planned time of dosing on Day 1 (i.e., 12 extractions); the extraction time points on Day 1 are: pre-dose, 0.25 h, 0.5 h, 0.75 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, and 24 h post-start of infusion

    Continuous ECG monitoring; subjects to be in supine position for at least 0.25 h before each extraction

  7. Telemetry ECG (Safety and Tolerability)

    Time frame: To commence approximately 10 min before dosing up to 6 h post-start of infusion

    No data are collected (safety monitoring); if cardiac monitoring shows a potentially significant abnormality, a clinical assessment of the subject will be performed, including a 12-lead ECG, and treatment given.

  8. Vital Signs (Safety and Tolerability)

    Time frame: Change from screening (3 to 28 d prior to dosing), admission (2 d prior to dosing), pre-dose (within 24 h prior to dosing), 0.25 h, immediately prior to end of infusion, 1, 2, 4, 6, 8, 12, 16, 24, 30, 36, and 48 h, and 7 d +/- 1 d post-start of infusion

    Blood pressure (mmHg), heart rate (bpm), oral temperature (degrees C or degrees F)

  9. Adverse Events (Safety and Tolerability)

    Time frame: 0.25 h post-start of infusion through 7 d +/- 1 d post-start of infusion (follow-up visit)

    All AEs are documented, including the date and time of onset, a description of the AE, severity, duration, actions taken, outcome and investigator's current opinion on the relationship between HBI-3000 and the event.

Secondary outcomes

  1. HBI-3000 Levels Over Time in Plasma (Cmax)

    Time frame: Change in Cmax from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Peak Plasma Concentration, Cmax (µg/mL)

  2. HBI-3000 Levels Over Time in Plasma (Tmax)

    Time frame: Change in Tmax from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Time to Reach the Peak Plasma Concentration, Tmax (h)

  3. HBI-3000 Levels Over Time in Plasma (AUC(0-last))

    Time frame: Change in AUC(0-last) from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Area Under the Plasma Concentration versus Time Curve from Time Zero to Time of Last Measurable Concentration, AUC(0-last) (µg·h/mL)

  4. HBI-3000 Levels Over Time in Plasma (AUC(0-inf))

    Time frame: Change in AUC(0-inf) from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Area Under the Plasma Concentration versus Time Curve from Time Zero to Infinity, AUC(0-inf) (µg·h/mL)

  5. HBI-3000 Levels Over Time in Plasma (AUC(0-24h))

    Time frame: Change in AUC(0-24h) from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Area Under the Plasma Concentration versus Time Curve from Time Zero to Time 24h, AUC(0-24h) (µg·h/mL)

  6. HBI-3000 Levels Over Time in Plasma (AUC%extrap)

    Time frame: Change in AUC%extrap from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Area Under the Plasma Concentration versus Time Curve Extrapolated from Time t to Infinity as a Percentage of total AUC, AUC%extrap (%)

  7. HBI-3000 Levels Over Time in Plasma (lambda-z)

    Time frame: Change in lambda-z from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Terminal Disposition Rate Constant/Terminal Rate Constant, lambda-z (1/h)

  8. HBI-3000 Levels Over Time in Plasma (T1/2)

    Time frame: Change in T1/2 from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Elimination Half Life, T1/2 (h)

  9. HBI-3000 Levels Over Time in Plasma (CL)

    Time frame: Change in CL from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Apparent Total Clearance of the Drug from Plasma, CL (mL/h·kg)

  10. HBI-3000 Levels Over Time in Plasma (CLr)

    Time frame: Change in CLr from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Renal Clearance of the Drug from Plasma, CLr (mL/h·kg)

  11. HBI-3000 Levels Over Time in Plasma (Vz)

    Time frame: Change in Vz from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Apparent Volume of Distribution during Terminal Phase, Vz (L/kg)

  12. HBI-3000 Levels Over Time in Plasma (Vss)

    Time frame: Change in Vss from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Apparent Volume of Distribution at Steady State, Vss (L/kg)

  13. HBI-3000 Levels Over Time in Plasma (MRT)

    Time frame: Change in MRT from pre-dose (within 24 h prior to dosing), and 0.25 h, immediately prior to end of infusion, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 16 h, 24 h, 30 h, 36 h, 48 h, 72 h post-start of infusion

    Mean Residence Time, MRT (h)

  14. HBI-3000 Levels Over Time in Urine (Ae)

    Time frame: Change in Ae from pre-dose (within 24 h prior to dosing), and 0-6 h, 6-12 h, 12-24 h post-start of infusion

    Amount of Unchanged Drug Excreted into the Urine, Ae (µg)

  15. HBI-3000 Levels Over Time in Urine (CumAe)

    Time frame: Change in CumAe from pre-dose (within 24 h prior to dosing), and 0-6 h, 6-12 h, 12-24 h post-start of infusion

    Cumulative Recovery of Unchanged Drug Excreted into the Urine, CumAe (µg)

  16. HBI-3000 Levels Over Time in Urine (%Ae)

    Time frame: Change in %Ae from pre-dose (within 24 h prior to dosing), and 0-6 h, 6-12 h, 12-24 h post-start of infusion

    Amount of Unchanged Drug Excreted into the Urine as a Percentage of the Administered Dose, %Ae (%)

  17. HBI-3000 Levels Over Time in Urine (Cum%Ae)

    Time frame: Change in Cum%Ae from pre-dose (within 24 h prior to dosing), and 0-6 h, 6-12 h, 12-24 h post-start of infusion

    Cumulative Recovery of Unchanged Drug Excreted into the Urine as a Percentage of the Dose, Cum%Ae (%)

Sponsors and collaborators

Lead sponsor

HUYABIO International, LLC.

Industry

Collaborators

  • Quotient Clinical

Registry information

Official study title

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Serial Cohort Dose-Escalation Study of Intravenously Administered HBI-3000

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Jan 12, 2018
Registry last updated
Aug 29, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.